
Sight Sciences (SGHT) Stock Forecast & Price Target
Sight Sciences (SGHT) Analyst Ratings
Bulls say
Sight Sciences Inc is positioned for positive financial growth, driven by anticipated revenue increases from its Surgical Glaucoma segment, which is expected to align with the overall market trends in minimally invasive glaucoma surgery (MIGS). The company is experiencing accelerated adoption of its TearCare System, alongside progress towards achieving profitability, which can further enhance its revenue potential. Projections for 2025 and 2026 indicate sustained revenue of $75 million and $82 million, respectively, with improvements anticipated in earnings per share (EPS), reflecting a positive trajectory for the company's financial outlook.
Bears say
Sight Sciences Inc. has reiterated its 2025 revenue guidance of $72-76 million while projecting a decline in Surgical Glaucoma revenue in the third quarter of 2025 by mid-single digits year-over-year. The company faces significant risks, including increasing competition in the minimally invasive glaucoma surgery (MIGS) market, delayed insurance coverage for its TearCare product, and ongoing cash burn without improvement. Additionally, management has decreased its adjusted operating expense guidance for 2025, which may signal challenges in maintaining operational efficiency amid these pressures.
This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.
Sight Sciences (SGHT) Analyst Forecast & Price Prediction
Start investing in Sight Sciences (SGHT)
Order type
Buy in
Order amount
Est. shares
0 shares